Complement activation drives antibody-mediated transfusion-related acute lung injury via macrophage trafficking and formation of NETs
Blood, vol. 143, pp. 79–91
Abstract
ABSTRACT: Transfusion-related acute lung injury (TRALI) is one of the leading causes of transfusion-related fatalities and, to date, is without available therapies. Here, we investigated the role of the complement system in TRALI. Murine anti-major histocompatibility complex class I antibodies were used in TRALI mouse models, in combination with analyses of plasma samples from patients with TRALI. We found that in vitro complement activation was related to in vivo antibody-mediated TRALI induction, which was correlated with increased macrophage trafficking from the lungs to the blood in a fragment crystallizable region (Fc)-dependent manner and that this was dependent on C5. Human immunoglobulin G 1 variants of the murine TRALI-inducing antibody 34-1-2S, either unable to activate complement and/or bind to Fcγ receptors (FcγRs), revealed an essential role for the complement system, but not for FcγRs, in the onset of 34-1-2S-mediated TRALI in mice. In addition, we found high levels of complement activation in the plasma of patients with TRALI (n = 53), which correlated with elevated neutrophil extracellular trap (NET) markers. In vitro we found that NETs could be formed in a murine, 2-hit model, mimicking TRALI with lipopolysaccharide and C5a stimulation. Collectively, this reveals a critical role of Fc-mediated complement activation in TRALI, with a direct relation to macrophage trafficking from the lungs to the blood and an association with NET formation, suggesting that targeting the complement system may be an attractive therapeutic approach for combating TRALI.
Authors 15
-
Sanquin · Amsterdam University Medical Centers · University of Amsterdam
Affiliation as printed
1Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
-
Sanquin · Amsterdam University Medical Centers · University of Amsterdam
Affiliation as printed
1Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
-
Sanquin · Amsterdam University Medical Centers · University of Amsterdam
Affiliation as printed
1Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
-
Sanquin · Amsterdam University Medical Centers · University of Amsterdam
Affiliation as printed
1Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
-
Affiliation as printed
2Sanquin Reagents, Amsterdam, The Netherlands
-
Affiliation as printed
2Sanquin Reagents, Amsterdam, The Netherlands
-
Affiliation as printed
2Sanquin Reagents, Amsterdam, The Netherlands
-
Sanquin · Amsterdam University Medical Centers · University of Amsterdam
Affiliation as printed
3Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, The Netherlands
-
Sanquin · Amsterdam University Medical Centers · University of Amsterdam
Affiliation as printed
3Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, The Netherlands
-
Sanquin · Emma Kinderziekenhuis · Amsterdam University Medical Centers · University of Amsterdam
Affiliation as printed
3Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, The Netherlands
4Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam UMC, Amsterdam, The Netherlands
-
Leiden University Medical Center · Sanquin · Amsterdam University Medical Centers · University of Amsterdam
Affiliation as printed
1Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
5Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands
6Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, The Netherlands
-
Affiliation as printed
5Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands
-
Sanquin · Amsterdam University Medical Centers · University of Amsterdam
Affiliation as printed
1Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
-
Sanquin · Amsterdam University Medical Centers · University of Amsterdam
Affiliation as printed
1Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
-
Sanquin · Amsterdam University Medical Centers · University of Amsterdam
Affiliation as printed
1Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
Cited by 51 stored of 51
Cited by patents worldwide 1 (Lens.org)
-
METHOD OF TREATING A DISORDER WITH A C5A INHIBITORWO2025196240A1 2025-09-25 Pending